Company news
Percheron Therapeutics Limited news in 2021
Percheron Therapeutics Limited's news releases, calls and decks from 2021, newest first.
Entitlement Offer Results
December 21, 2021
Annual General Meeting Presentation
December 14, 2021
Positive UK PIP Decision & PDCO opinion ratification by EMA
December 13, 2021
ATL1102 Toxicology Protocol submitted to US FDA
December 8, 2021
Investor Presentation
November 1, 2021
Positive PDCO opinion and A$20m Placement
November 1, 2021
Positive feedback received on Paediatric Investigation Plan
September 30, 2021
New data supports ATL1102s broader clinical potential
September 23, 2021
ANP to present new proteomics data at WMS Congress 2021
September 19, 2021
ANP Updates on US Regulatory Plans for ATL1102 in DMD
August 11, 2021
ANP and MCRI new R&D collaboration for ATL1102
June 28, 2021
ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
June 21, 2021
US FDA Feedback on Type C Meeting for ATL1102 in the US
June 1, 2021
Manufacture of ATL1102 clinical supplies for Phase IIb trial
May 26, 2021
US FDA Type C Meeting for ATL1102 in DMD
April 23, 2021
ATL1102 DMD Paediatric Investigation Plan submitted to EMA
February 24, 2021
Half Yearly Report and Half Year Accounts
February 24, 2021
ANP meeting with US FDA granted for ATL1102 in DMD
February 14, 2021
Quarterly Update and Appendix 4C
January 27, 2021
Decks in 2021
- Shareholder Meeting (December 2021)
Shareholder meeting · 21 slides · Dec 15, 2021
- Investor Presentation (November 2021)
Investor deck · 42 slides · Nov 1, 2021